For Dr. Choi’s Epub study “Combination index of sTfR and MCH for evaluating iron deficiency in end-stage renal disease”

2007 ◽  
Vol 86 (7) ◽  
pp. 545-545 ◽  
Author(s):  
Anastasios Koulaouzidis ◽  
Elmuhtady Said ◽  
Athar A. Saeed
2017 ◽  
Vol 46 (6) ◽  
pp. 488-497 ◽  
Author(s):  
Finnian R. Mc Causland ◽  
Brian Claggett ◽  
Marc A. Pfeffer ◽  
Emmanuel A. Burdmann ◽  
Kai-Uwe Eckardt ◽  
...  

Background: The pathogenesis of chronic kidney disease associated anemia is multifactorial and includes decreased production of erythropoietin (EPO), iron deficiency, inflammation, and EPO resistance. To better understand the trajectory of these parameters, we described temporal trends in hemoglobin (Hb), ferritin, transferrin saturation, C-reactive protein (CRP), and darbepoetin dosing in the Trial to Reduce cardiovascular Events with Aranesp Therapy (TREAT). Methods: We performed a post hoc analysis of 4,038 participants in TREAT. Mixed effects linear regression models were used to determine the trajectory of parameters of interest prior to end-stage renal disease (ESRD). Likelihood ratio tests were used to determine the overall differences in biomarker values and differences in trajectories between those who did and did not develop ESRD. Results: Hb declined precipitously in the year prior to the development of ESRD (irrespective of treatment assignment), and was on average 1.15 g/dL (95% CI –1.26 to –1.04) lower in those who developed ESRD versus those who did not, at the time of ESRD/end of follow-up. Simultaneously, the mean darbepoetin dose and CRP concentration increased, while serum ferritin and transferrin saturations were >140 μg/L and 20%, respectively. Conclusions: Our analyses provide descriptive insights regarding the temporal changes of Hb, darbepoetin dose, and related parameters as ESRD approaches in participants of TREAT. Hb declined as much as 1–2 years prior to the development of ESRD, without biochemical evidence of iron deficiency. The most precipitous decline occurred in the months immediately prior to ESRD, despite administration of escalating doses of darbepoetin and in parallel with an increase in CRP.


1999 ◽  
Vol 12 (4) ◽  
pp. 231-234 ◽  
Author(s):  
Sanjeev Mittal ◽  
John K. Maesaka ◽  
Steven Fishbane

e-CliniC ◽  
2016 ◽  
Vol 4 (1) ◽  
Author(s):  
Felix E. Suyatno ◽  
Linda W. A. Rotty ◽  
Emma S. Moeis

Abstract: Chronic kidney disease (CKD) is a pathophysiological process with varied etiology, results in progressive decrease of renal function, and generally ends up with renal failure. Data from Indonesian Association of Nephrology (PERNEFRI) in 2012 showed that 83% of all patients who underwent hemodialysis were with end-stage renal disease (ESRD) which is the terminal stage of CKD. In patients with CKD, there can be a wide variety of complications; one of them is anemia. This study aimed to obtain the overview of iron deficiency anemia of stage V CKD patients who were treated with hemodialysis in hemodialysis center of Prof. Dr. R. D. Kandou Central General Hospital Manado. This was a descriptive study with a cross sectional approach conducted from October to December 2015 in Prof. Dr. R. D. Kandou Hospital. Variables were age, sex, laboratory result, duration of hemodialysis, and the diagnosis of iron deficiency anemia. The results showed that there were 39 samples; females were 21 patients (53.8%). The largest age group was >60 years with 16 patients (41%). The degree of anemia mostly found was the moderate degree with 26 patients (66.7%). Five patients (12.8%) were diagnosed with iron deficiency anemia. Conclusion: In this study, the most common degree of anemia was moderate, followed by severe and slight anemia consecutively. Iron deficiency anemia cases were 12.8%. Keywords: chronic kidney disease, iron deficiency anemia, serum iron, transferrin saturation  Abstrak: Penyakit ginjal kronik (PGK) adalah suatu proses patofisiologik dengan etiologi beragam, mengakibatkan penurunan fungsi ginjal yang progresif, dan umumnya berakhir dengan gagal ginjal. Data dari Perkumpulan Nefrologi Indonesia (PERNEFRI) tahun 2012 menyatakan bahwa 83% dari seluruh pasien yang menjalani hemodialisis ialah pasien end stage renal disease (ESRD) yang merupakan stadium terminal PGK. Pada pasien PGK, dapat terjadi berbagai macam komplikasi, salah satunya ialah anemia Penelitian ini bertujuan untuk mengetahui gambaran anemia defisiensi besi pada pasien PGK stadium V yang menjalani hemodialisis di Instalasi Tindakan Hemodialisis RSUP Prof. Dr. R.D. Kandou Manado. Penelitian ini menggunakan metode deskriptif dengan pendekatan potong lintang berdasarkan data primer pada Bulan Oktober – Desember 2015. Variabel penelitian yang digunakan yaitu umur, jenis kelamin, hasil laboratorium, lama menjalani hemodialisis, dan diagnosis anemia defisiensi besi. Hasil penelitian memperlihatkan 39 sampel dengan distribusi sampel terbanyak ialah perempuan sebanyak 21 orang (53,8%), golongan umur terbanyak > 60 tahun sebanyak 16 orang (41%), derajat anemia terbanyak ditemukan ialah anemia derajat sedang sebanyak 26 orang (66,7%), dan terdapat 5 orang (12,8%) yang terdiagnosis anemia defisiensi besi. Simpulan: Pada penelitian ini ditemukan anemia derajat sedang yang terseing, diikuti anemia derajat berat dan ringan. Terdapat 12,8% pasien dengan anemia defisiensi besi. Kata kunci: penyakit ginjal kronik, anemia defisiensi besi, serum iron, saturasi transferin


Sign in / Sign up

Export Citation Format

Share Document